IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
29.04
-0.44 (-1.49%)
At close: Apr 28, 2026, 4:00 PM EDT
29.44
+0.40 (1.38%)
After-hours: Apr 28, 2026, 5:01 PM EDT
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for IDEAYA Biosciences stock have an average target of 52.86, with a low estimate of 35 and a high estimate of 79. The average target predicts an increase of 82.02% from the current stock price of 29.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 9 | 9 | 8 | 9 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $31 → $35 | Hold | Maintains | $31 → $35 | +20.52% | Apr 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $44 → $48 | Buy | Maintains | $44 → $48 | +65.29% | Apr 14, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $49 → $53 | Buy | Maintains | $49 → $53 | +82.51% | Apr 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $52 → $58 | Buy | Maintains | $52 → $58 | +99.72% | Apr 14, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $50 → $54 | Strong Buy | Maintains | $50 → $54 | +85.95% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
42.55M
from 218.71M
Decreased by -80.54%
Revenue Next Year
128.11M
from 42.55M
Increased by 201.05%
EPS This Year
-4.04
from -1.28
EPS Next Year
-3.69
from -4.04
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 103.3M | 259.2M | ||||||
| Avg | 42.6M | 128.1M | ||||||
| Low | n/a | 53.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -52.8% | 509.0% | ||||||
| Avg | -80.5% | 201.1% | ||||||
| Low | - | 26.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.15 | -2.73 | ||||||
| Avg | -4.04 | -3.69 | ||||||
| Low | -4.74 | -4.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.